Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
18.82
+0.42 (2.26%)
Jan 21, 2026, 11:51 AM EST - Market open
Evommune Revenue
Evommune had revenue of $10.00M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $13.00M. In the year 2024, Evommune had annual revenue of $7.00M with 40.00% growth.
Revenue (ttm)
$13.00M
Revenue Growth
+40.00%
P/S Ratio
2.18
Revenue / Employee
$288,889
Employees
45
Market Cap
593.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEVMN News
- 5 weeks ago - Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Evommune Announces Pricing of its Initial Public Offering - PRNewsWire
- 2 months ago - Evommune Announces Commencement of Initial Public Offering - PRNewsWire
- 3 months ago - Evommune Aims For IPO In Bifurcated Biopharma Market - Seeking Alpha
- 3 months ago - Evommune files for IPO to advance immune drug work - BioPharma Dive
- 3 months ago - Evommune IPO Registration Document (S-1) - SEC
- 3 months ago - Chronic inflammatory disease biotech Evommune files for a $100 million IPO - Renaissance Capital